HOLLISTON, Mass., Feb. 14, 2014 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, will announce results for its fourth quarter and year ended December 31, 2013 before market trading hours on Thursday, February 27, 2014. A conference call to discuss the company's fourth quarter and year-end financial results is scheduled for that same day at 11:00 AM ET.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience.
Investors can access the live conference call by dialing the following phone numbers: toll-free 877-303-7611, or international: 970-315-0445, and referencing the pass code "55082311".
The conference call will be simultaneously broadcast over the Internet and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the website at www.harvardbioscience.com and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, a replay will be available from approximately 2:00 PM ET on February 27, 2014 through March 8, 2014 and will be accessible by dialing toll-free 855-859-2056, or toll and international 404-537-3406, and referencing the pass code of "55082311". The webcast of the call will be archived in the investor relations section of the website.
Schedule this webcast into MS-Outlook calendar (click open when prompted):
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer, and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research. Our products are sold to thousands of researchers in over 100 countries primarily through our 850 page catalog (and various other specialty catalogs), our website, through distributors, including GE Healthcare, Thermo Fisher Scientific, and VWR, and via our field sales organization. Harvard Bioscience has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, and Spain with additional facilities in France and Canada. For more information, please visit our website at www.harvardbioscience.com.
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the anticipated savings, cost reductions, restructuring charges and reinvestment amounts. These statements involve risks and uncertainties, including among other things, market conditions and other factors that may cause the actual results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Bioscience expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
The Harvard Bioscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6426
For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site.
CONTACT: Harvard Bioscience, Inc. Jeffrey A. Duchemin President and Chief Executive Officer Tel: (508) 893-8999 Investor and Public Relations: Dian Griesel Inc. Cheryl Schneider/Susan Forman (212) 825-3210
Source:Harvard Bioscience, Inc.